GlassScriptPhysician profile
Shien Hu
NPI 1366766966
$4,544.03
in general payments reported to CMS, 2019-2025
26 companies · $1,910 in 2025
The $1,910 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $583 · 2024: $2,051 · 2025: $1,910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,544.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $735.21 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $470.62 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $360.63 | 2023-2025 | Trulance, Xifaxan, Relistor |
| Abbvie INC. | $293.93 | 2024-2025 | |
| Janssen Biotech, INC. | $254.53 | 2023-2025 | Tremfya, Stelara, Remicade |
| Celgene Corporation | $238.46 | 2023-2024 | Zeposia |
| Ardelyx, INC. | $237.52 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $212.80 | 2024-2025 | |
| Lilly USA, LLC | $210.16 | 2024-2025 | Omvoh, Zepbound |
| Genzyme Corporation | $199.53 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $169.29 | 2023-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $148.87 | 2024-2025 | Voquezna |
| Fresenius Kabi USA, LLC | $146.03 | 2023-2025 | Idacio |
| Madrigal Pharmaceuticals | $144.91 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $129.00 | 2024-2025 | Iqirvo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $123.33 | 2023-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $111.60 | 2023-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $79.83 | 2023-2024 | Linzess |
| Daiichi Sankyo INC. | $65.94 | 2024 | Injectafer |
| Celltrion USA INC. | $56.54 | 2024-2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $34.32 | 2024 | Dificid, Zinplava |
| Alnylam Pharmaceuticals INC. | $34.28 | 2024-2025 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.06 | 2023 | Cyltezo |
| Mauna Kea Technologies, INC. | $21.53 | 2024 | |
| Exact Sciences Corporation | $16.62 | 2024 | Cologuard Collection Kit |
| Sandoz INC. | $14.49 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shien Hu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.